Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma
University of California, San Francisco · University of Southampton
Abstract
IgE plays an important role in allergic asthma. We hypothesized that reducing IgE in the airway mucosa would reduce airway inflammation. Forty-five patients with mild to moderate persistent asthma with sputum eosinophilia of 2% or more were treated with humanized monoclonal antibody against IgE (omalizumab) (n = 22) or placebo (n = 23) for 16 weeks. Outcomes included inflammatory cells in induced sputum and bronchial biopsies, and methacholine responsiveness. Treatment with omalizumab resulted in marked reduction of serum IgE and a reduction of IgE+ cells in the airway mucosa. The mean percentage sputum eosinophil count decreased significantly (p
Citation impact
- FWCI
- 19.33
- Percentile
- 100%
- References
- 51
Authors
12- RDRatko DjukanovićCorresponding
University of California, San Francisco, University of Southampton
- SJSusan J. Wilson
University of California, San Francisco, University of Southampton
- MKMonica Kraft
University of California, San Francisco, University of Southampton
- NNNizar N. Jarjour
University of California, San Francisco, University of Southampton
- MDMark D. Steel
University of California, San Francisco, University of Southampton
Topics & keywords
- Omalizumab
- Medicine
- Immunoglobulin E
- Methacholine
- Immunology
- Asthma
- Eosinophilia
- Sputum
- Good health and well-being